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Abstract
Background: Quality of life (QOL) has become an important item in health care. QOL should be a major target of
treatment in chronic diseases such as rheumatoid arthritis (RA) and sarcoidosis. The aim of this study was to compare the
impact of RA and sarcoidosis on patients’ QOL. We expected more serious impairment of QOL in the RA group than in the
sarcoidosis group.
Methods: QOL was studied in RA patients (n 5 32), sarcoidosis patients (n 5 37), and a healthy control group (n 5 37)
employing the World Health Organization Quality of Life assessment instrument (WHOQOL-100).
Results: In both patient groups QOL was impaired with respect to Physical Health, Level of Independence (P , 0.001),
and Overall QOL and General Health (P , 0.01). Moreover, RA patients appeared to have a lower QOL with respect to Pain
and Discomfort (P , 0.001) and Mobility (P , 0.001).
Conclusions: In RA and sarcoidosis, fatigue and sleep were major problems. In contrast to our expectations, with respect
to activities of daily living and working capacity, the two patient groups did not show any difference. Impairment of QOL
was more serious and included more aspects of QOL in RA than in sarcoidosis. (See Editorial p. 83.)  1999 Elsevier
Science B.V. All rights reserved.
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Introduction tients with chronic diseases, including rheumatoid
arthritis (RA) [1–5]. Improvement of patients’ QOL
In the past two decades, assessment of health has become a major target of treatment. In general,
status and quality of life (QOL) as an outcome health status and QOL of RA patients are substantial-
measure has become increasingly important in pa- ly impaired, whereas disease status as assessed by
disease related variables does not reflect accurately
the impact of the disease on psychological and social*Corresponding author. Tel.: 1 31-43-3877043; fax: 1 31-43-
3875051; e-mail: mdr@slon.azm.nl well-being [4,6]. In sarcoidosis, health status and
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QOL have had little attention. Recently, we found Therefore, the aim of this study was to compare the
impairment of health status and QOL in sarcoidosis impact on QOL of RA and sarcoidosis. Recently, we
patients [7,8]. No relationship of routinely performed showed that QOL in symptomatic sarcoidosis pa-
pulmonary function tests and serum angiotensin tients was more seriously impaired than QOL in
converting enzyme (sACE) with health status and patients without current symptoms [8]. We hypoth-
QOL was found [7,8]. esized that QOL would be impaired in RA as well as
Sarcoidosis and rheumatoid arthritis (RA) have sarcoidosis compared to healthy controls. Sarcoidosis
several sequelae in common. Both are inflammatory patients were expected to have better QOL than RA
disorders of unknown etiology. In both disorders the patients. Especially with respect to pain and levels of
mode of onset is variable and they both regularly independence we expected a more serious impair-
occur in relatively young people. The clinical course ment of QOL in the RA patients. With respect to
in both disorders is rather unpredictable, ranging fatigue no difference between the patient groups was
from spontaneous remission to rapid progression or a expected. Therefore, in the present study QOL in
more chronic course. Some immunologic disturbance active RA was compared with QOL of symptomatic
is thought to play a central role in the pathogenesis sarcoidosis patients. For this purpose a broad-ranging
of sarcoidosis [9] as well as in RA [10]. Mani- generic QOL instrument, the World Health Organiza-
festations of RA are primarily in the joints, but tion Quality of Life assessment instrument
systemic symptoms and extra-articular inflammation (WHOQOL-100) [19], was used.
may be present as well. In RA, as in sarcoidosis,
pulmonary involvement with interstitial pneumonitis
or fibrosis, however only occasionally, may occur Materials and methods
[11,12]. In sarcoidosis, symptoms vary considerably
depending on the organ involvement. Patients with Patients
sarcoidosis may present with aspecific symptoms
also present in RA such as fatigue, arthralgia, and A group of RA patients (n 5 35) was recruited
muscle pain. In a previous study, we found that in aselectively from consecutive patients with RA not
about 5% of patients with sarcoidosis, the symptoms in remission visiting the Outpatient Department of
were initially attributed to a RA [13]. Finally, in both Rheumatology, Rijnstate Hospital, Arnhem. When
disorders no specific causal treatment is known at asked to participate in the study, three patients
present. refused for various reasons, whereas 32 patients
In rheumatology a number of health status mea- agreed to participate in the study. None of those
sures have been used to assess QOL [4]. Recently, latter patients had any co-morbidity. The diagnosis
Ruta et al. validated the SF-36, a generic health of RA was based on the American College of
status measure, in RA patients [14]. However, usual- Rheumatology (formerly the American Rheumatism
ly, disease impact of RA on patients’ lives has been Association) criteria for RA [20]. The patients were
assessed rather by disease-specific health status clinically assessed by a rheumatologist, who com-
measures [5,15–17] than by subjective QOL mea- pleted a questionnaire with the clinical characteris-
sures. Health status measures assess mainly func- tics: disease duration, functional class according to
tional status, whereas QOL instruments assess the Steinbrocker [21], current serum markers (erythro-
individuals’ subjective perception of their life. When cyte sedimentation rate (ERS) and C-reactive protein
using health status measures, it would be a mistake (CRP)), 28 swollen joint index, and current medica-
to equate lower levels of functioning with lower tion. At the same visit the patient completed the
QOL. For this conclusion would contrast with find- WHOQOL-100 [19].
ings in QOL research reflecting high perceived QOL The sarcoidosis patient group was recruited from
in spite of low levels of functioning [18]. eight Dutch hospitals (Rijnstate Hospital, Arnhem;
To the best of our knowledge, there exist no Academic Hospital St Radboud, Nijmegen; Rehabili-
comparative studies on QOL in RA and other tation Center Dekkerswald, Nijmegen; District
chronic inflammatory disorders such as sarcoidosis. Hospital Middle Twente, Hengelo; St. Jans-Hospital,
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Table 2Weert; Maasland Hospital, Sittard; The Wever
Characteristics of the RA patient groupHospital, Heerlen; and University Hospital, Maas-
Variabletricht). Seventy-one unselected consecutive out-pa-
atients with sarcoidosis, without any co-morbidity Disease duration, years 8.4 (9.3)
were contacted. Seven sarcoidosis patients declined Type RA seropositive /seronegative 26/4
Steinbrocker I / II / III / IV 9/22/1 /0for various reasons, but 64 agreed to participate. The
a28 swollen joint index 8.3 (8.0)diagnosis of sarcoidosis was based on clinical find- aCRP 25.9 (34.2)
ings, along with histological evidence. None of the aESR 33.7 (25.8)
patients had any previous medical condition which Corticosteroid use yes /no 5/27
might have influenced their QOL. All patients com- Present treatment with DMARDs yes /no 31/1
aNumber of DMARDs in the past 2.2 (2.3)pleted the WHOQOL-100. In addition, the physician
aasked them whether they had any of the following Data are means (SD); CRP 5 C-reactive protein, normal levels
, 9 U/ l; ESR 5 erythrocyte sedimentation rate; DMARDs 5complaints: fatigue, dyspnea, coughing, arthralgia, or
disease modifying anti-rheumatic drugs.erythema nodosum. Twenty-seven out of the 64
studied sarcoidosis patients reported no actual symp-
toms, whereas 37 patients appeared to suffer from mg/day, one with 15 mg/day, and of one patient
one or more symptom(s). In order to be able to information on the dose was missing. Only one
compare the impact of symptoms between sar- patient did not receive disease modifying anti-
coidosis patients and the studied RA patients, who rheumatic drugs (DMARDs) at the time of the study.
were not in remission, only sarcoidosis patients with Ten patients were currently treated with Methothre-
current symptoms related to their disorder (n 5 37) xate, nine with Sulphasalazine, four with Azathio-
were included in the present study. Using the patient prine, three with Penicillamine, two with Hydroxy-
record, the values of serum angiotensin converting chloroquine, one with Auromyosis, and one patient
enzyme (sACE) levels and the pulmonary function received the combination Sulphasalazine and Meto-
tests were obtained from the visit closest to the threxate at the time of the study.
session in which the questionnaires were completed. The characteristics of the sarcoidosis patients are
Furthermore, 240 control persons were recruited summarized in Table 3. The sarcoidosis patients
who were willing to participate in a study on QOL.
From the group of persons who returned a completed
Table 3
test-booklet (n 5 178; 74.2%), healthy control sub- Characteristics of the sarcoidosis patient group
jects (n 5 37) were selected on the basis of gender
Variable
and age, matched for the sarcoidosis patients. For
aDisease duration 4.4 (5.1)demographical characteristics of the two patient
FEV (normal /decreased) 29/81groups and the control group see Table 1.
T L,CO (normal /decreased) 22/15
aThe characteristics of the RA patients are summa- sACE U/l (9–25 U/ l) 30 (25)
rized in Table 2. During the previous week five of Use of corticosteroids (yes /no) 14/23
the RA patients had received systemic corticoste- a Data are means (SD); FEV 5 forced expiratory volume in one1
roids; all these patients received prednisolone. One second; T L,CO 5 transfer factor of the lung for carbon monoxide;
patient was treated with 7.5 mg/day, two with 10 sACE 5 serum angiotensin converting enzyme.
Table 1
Characteristics of the studied sarcoidosis patients, rheumatoid arthritis (RA) patients, and the healthy control group
Variable RA patients Sarcoidosis patients Control group
Number 32 37 37
aAge, year 54.3 (29–70) 45.3 (26–73) 45.4 (26–73)
Gender male / female 13/19 21/16 21/16
a Data are means with the range in parentheses.
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reported the following symptoms: fatigue in 28, (60–80%); (3) moderate decrease (40–60%); (4)
dyspnea in 15, arthralgia in 11, cough in six patients, severe decrease ( , 40%), of the values predicted.
and erythema nodosum in one patient. With respect
to the pulmonary function tests, eight of the sar-
Statistical methods
coidosis patients (21.6%) showed a mildly decreased
forced expiration volume in one second (FEV ), and1 Data are expressed as mean (SD) and, if appro-
15 patients showed a decreased transfer factor of the
priate, as mean with range. Statistical differences in
lung for carbon monoxide (T L,CO). In 12 of the
age and gender between patient groups were studied
patients the T L,CO was mildly decreased and in three 2using Student’s t-tests and x -tests. Pearson correla-
patients it was moderately decreased, according to
tion coefficients were used. Significance was ac-
the American Medical Association classes.
cepted with P-values , 0.05. Furthermore, data were
analyzed using analysis of variance (ANOVA) with
Questionnaire
age and gender as covariates between groups. Within
the RA group one-way analyses of variance were
Both patient groups and the healthy controls
used. In ANOVA, significance was accepted with
completed the World Health Organization Quality of
P-values , 0.01 due to the number of analyses. All
Life assessment instrument, WHOQOL-100, (Dutch
analyses were performed using the Statistical Pack-
version) [19]. This is a cross-culturally developed
age for Social Science (SPSS) for Windows [25].
generic multidimensional QOL measure that has
been simultaneously developed in 15 centres around
the world, e.g. in France, Russia, USA, Panama,
Zimbabwe, Japan, Thailand, and The Netherlands Results
[22]. It consists of 100 items assessing 24 facets of
QOL within six domains (Physical Health, Psycho- The RA patients were significantly older than the
logical Health, Level of Independence, Social Rela- sarcoidosis patients (P , 0.001). Table 4 summarizes
tionships, Environment, and Spirituality /Religion / the QOL scores for domains and facets with signifi-
Personal Beliefs) and a general evaluative facet cant differences between the groups. Impairment was
(Overall Quality of Life and General Health). Each found with respect to the evaluative facet Overall
facet is represented by four items. The response scale QOL and General Health, the domains Physical
is a 5-point Likert scale, scores can range from 4 to Health and its facets, as well as the domain Level of
20. Except for the facets Pain and Discomfort, Independence and its facets, for both patient groups.
Negative Feelings, and Dependence on Medication The facets Overall QOL and General Health (F 5
and Treatment, higher scores mean a better QOL. 7.4; df 5 2, P , 0.01), Energy and Fatigue (F 5
The reliability and validity of the Dutch version of 16.5; df 5 2, P , 0.001), Sleep and Rest (F 5 9.8;
the instrument are high [19,23]. df 5 2, P , 0.001), Activities of Daily Living (F 5
18.1; df 5 2, P , 0.001), and Working Capacity (F 5
Pulmonary function tests 18.5; df 5 2, P , 0.001) were low in the two patient
groups compared to the healthy controls.
Pulmonary function measurements of the sar- In the domains Physical Health (F 5 18.1; df 5 2,
coidosis patients included the FEV (Compactbody, P , 0.001) as well as Level of Independence (F 51
¨Jaeger, Wurzburg, Germany). The best measure of 26.6; df 5 2, P , 0.001) and its facet Dependence on
three efforts was selected. All volumes are expressed Medication or Treatment (F 5 41.2; df 5 2, P ,
as percentages of the reference values [24]. The 0.001) all three groups scored significantly different
T L,CO was measured using the single breath method from each other, the healthy controls having the
¨(Masterlab, Jaeger, Wurzburg, Germany). Four highest QOL in these areas and the RA group the
ranges of FEV and T L,CO levels were classified lowest. Furthermore, the group of RA patients scored1
according to the American Medical Association worse on the facets Pain and Discomfort (F 5 16.1;
classes: (1) normal ( . 80%); (2) mild decrease df 5 2, P , 0.001) and Mobility (F 5 6.9; df 5 2,
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Table 4
WHOQOL-100 domain and facet scores with significant differences between the rheumatoid arthritis (RA) patients, the sarcoidosis patients,
aand the matched control group
WHOQOL-100 RA Sarcoidosis Control
group group group
b,fOverall Quality of Life and General Health 13.6 (2.5) 14.2 (3.7) 16.2 (2.3)
c,ePhysical Health 12.3 (2.6) 14.3 (2.8) 16.1 (1.7)
d,ePain and Discomfort 12.9 (2.7) 9.2 (3.1) 9.1 (2.8)
b,eEnergy and Fatigue 11.7 (3.6) 12.2 (3.7) 15.8 (2.0)
b,eSleep and Rest 14.0 (3.7) 14.8 (3.8) 17.4 (2.5)
c,eLevel of Independence 12.1 (2.9) 13.9 (3.3) 17.4 (2.3)
d,fMobility 13.6 (2.5) 15.5 (3.4) 17.2 (3.3)
b,eActivities of Daily Living 12.8 (3.5) 13.4 (3.7) 17.2 (2.1)
c,eDependence on Medication or Treatments 13.8 (3.0) 10.0 (4.2) 5.7 (2.7)
b,eWorking Capacity 12.1 (3.5) 12.8 (4.2) 17.0 (2.9)
a Analysis of variance (covariates age); scores are means (SD).
b Control group scored differently from the two patient groups.
c All three groups scored differently from each other.
d RA group scored differently from the two other groups.
e P , 0.001.
f P , 0.01. Note: domains are printed in bold; for the facets Pain and Discomfort and Dependence on Medication or Treatment higher
scores mean worse QOL.
P , 0.01) than the sarcoidosis patients and the P , 0.05) as well as Spirituality /Religion /Personal
healthy group. Beliefs (r 5 2 0.41, P , 0.05) and the doses of
For the RA patients we found a significant correla- systemic corticosteroids.
tion between the evaluative facet Overall QOL and On the facet level, Energy and Fatigue correlated
General Health and the facet Pain and Discomfort with the number of courses with DMARDs in the
(r 5 2 0.65, P , 0.001). Moreover, a relationship past (r 5 2 0.50, P , 0.01), and the doses of sys-
was found between the facet Energy and Fatigue and temic corticosteroids (r 5 2 0.39, P , 0.05). More-
the facet Pain and Discomfort (r 5 2 0.69, P , over, RA patients with elevated CRP levels showed
0.001). (Note, that for the facet Pain and Discomfort, even lower scores for Energy and Fatigue (t 5 2.95,
in contrast to most other facets, higher scores mean a df 5 12, P 5 0.012) than those with normal CRP.
worse QOL). No relationship was found for the facet The facet Sleep and Rest correlated with the ESR
Pain and Discomfort with Sleep and Rest and (r 5 2 0.54. P , 0.001). The facets Thinking, Learn-
between the facets Energy and Fatigue and Sleep and ing, Memory, and Concentration and Bodily Image
Rest. Although the RA patients did not show an and Appearance were related to the swollen joint
impairment of their psychological health, the facet index (r 5 2 0.39, P , 0.05 and r 5 2 0.40, P ,
Energy and Fatigue was related to the domain 0.05, respectively). Mobility correlated with the ESR
Psychological Health of the WHOQOL-100 (r 5 (r 5 2 0.48, P , 0.01). Moreover, a relationship was
0.75, P , 0.001). For the sarcoidosis patients no found between Activities of Daily Living and the
such relationship was found. number of courses of DMARDs (r 5 2 0.40, P ,
For the RA patients, several relationships were 0.05). The QOL facets Ability to Acquire New
found between the physiological measures of disease Information and Skills was related to the number of
severity and QOL. On the domain level, a relation- courses with DMARDs (r 5 2 0.41, P , 0.05) and
ship was found between Physical Health and the the doses of systemic corticosteroids (r 5 2 0.47,
ESR (r 5 2 0.50, P , 0.01), Level of Independence P , 0.01). No relationships were found between the
and number of courses with DMARDs (r 5 2 0.35, QOL facet Pain and Discomfort and any of the
P 5 0.05), and between Environment (r 5 2 0.42, physiological measures of disease severity. In addi-
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Fig. 1. Relationships between functional classes and the domains Physical Health, Level of Independence, and Overall QOL and General
Health.
tion, no relationship was found between gender, Discussion
duration of the disease, and the current medication
with DMARDs and patients’ QOL. Fig. 1 shows the Generally, parameters of disease activity or pro-
relationship between the functional class and the gression in RA are measured by the disease activity
domains Physical Health, Level of Independence, score (DAS). The DAS has shortcomings with
and the evaluative facet Overall Quality of Life and respect to the subjective feeling the RA patient has.
General Health. In Fig. 2., the relationship between In this study, we compared quality of life (QOL) in
the facets of these two domains and the functional RA with QOL in sarcoidosis using the WHOQOL-
class is illustrated. 100. The results showed that compared with healthy
The domain Psychological Health (F 5 5.4, df 5 control subjects, QOL was impaired in both RA
2; P , 0.05), and its facets Self-Esteem (F 5 9.0, patients and sarcoidosis patients in many aspects of
df 5 2; P , 0.001) and Negative Feelings (F 5 7.5, daily life. Compared to sarcoidosis patients, the
df 5 2; P , 0.01) were related to positivity of the impairment of QOL in RA patients was more severe
rheumatoid factor (RF). Scores for both facets were and included more aspects of daily life.
higher in patients with positivity for RF than in those Both patient groups felt anergic and suffered from
with a positivity for APF or seronegativity for RF, fatigue. Recurrent or persistent fatigue is a feature of
indicating that patients with a positive RF had a many acute or chronic inflammatory conditions.
better psychological health, more self-esteem, and Fatigue is generally recognized as a subjective
less negative feelings. feature in RA not being in clinical remission [26].
For the sarcoidosis patients, no relationships were Crosby found in a patient group with RA that more
found between physiological measures, that is sACE than 50% of patients suffered from fatigue and
levels as well as pulmonary function tests, and QOL. constant lack of energy [27]. Furthermore, in another
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Fig. 2. Relationships between functional classes and the facets of the domains Physical Health and Level of Independence.
study she demonstrated a correlation of pain, frag- found, that patients with RA have to cope simul-
mented sleep, and functional ability with fatigue in taneously with pain, limitations and dependence and
RA patients [28]. In the present study, pain and that all three factors were negatively related to QOL
fatigue were interrelated in the RA patients. How- [32]. Moreover, depressive symptoms are more
ever, no interrelationships of pain and fatigue with frequent in patients with RA than in healthy controls,
sleep were found, although all three aspects were even after controlling for criterion contamination
significantly impaired. In sarcoidosis, the symptom [31,33]. In the present study, the RA patients as a
fatigue has received little attention in literature [29]. group were not impaired with respect to their
Recently, we found lower levels of energy and more psychological health. However, patients with lower
fatigue in a group of sarcoidosis patients compared levels of energy showed more impairment of their
to healthy controls. This finding was not associated psychological health. In rheumatology research, the
with current symptoms; it appeared to be present also negative affect component of QOL has been empha-
in patients who initially had reported no symptoms sized [31]. In the present study, RA patients did not
[8]. In another study, we found besides reduced have more negative feelings than sarcoidosis patients
respiratory muscle strength and respiratory muscle and healthy controls. However, patients with
endurance, an interrelationship between the symptom seropositivity for rheumatoid factor (RF) showed
fatigue and decreased expiratory muscle strength better psychological health, less negative feelings,
[30]. and a better self-esteem compared with positivity for
RA can have a negative effect on affective, APF. Fewer psychopathological tendencies in pa-
behavioral, and social functioning of patients [31]. tients with positivity for RF than in those with
Studying psychological stressors in RA, others have seronegativity for RF have been reported before [34].
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Also the sarcoidosis patients included in this study asking patients, whether they have complaints [8].
were not impaired in their psychological health. We The WHOQOL-100 facet Energy and Fatigue ap-
found no relationship between psychological health pears to be sensitive for the assessment of fatigue in
and fatigue. With respect to depressive symptoms in RA patients as well.
sarcoidosis patients, we found in a previous study Physiological measures such as ESR and the
that patients with current symptoms experienced current medication as well as medication in the past
more depressive symptoms than asymptomatic pa- were related to only a few aspects of QOL. As
tients [7]. discussed above, elevated CRP levels correlated with
In the present study, the QOL in both patient patients’ pain and discomfort. No relationship was
groups was impaired mainly with respect to aspects found between duration of the disease and QOL. In
of physical health and level of independence, as well general, non-significant correlations were found be-
as general health and overall QOL. As discussed tween QOL and the routinely performed physiologi-
above, with respect to fatigue and sleeping problems, cal measures. These results are in line with other
the two patient groups did not differ significantly studies that have shown that disease status in RA,
from each other. Also difficulties performing ac- assessed by the routinely performed measures of
tivities of daily living and work were equally im- physical health, did not reflect the impact of RA on
paired in both patient groups. In addition, the RA psychosocial well-being [38]. Self-reported low
patients were impaired in their mobility. Also pain physical well-being, however, was associated with
and discomfort appeared to be a major problem only more depressive feelings [6]. Other subjective stres-
in RA patients. This could be expected, as chronic sors such as perceived limitation and dependence
and acute pain is known to be the major consequence were found only weakly related to traditionally used
of this disorder [31,32]. Surprisingly, no relationship disease status measures [32].
was found between the levels of pain of RA patients For the sarcoidosis patients no relationship be-
assessed by the WHOQOL-100 and any of the tween pulmonary function tests such as FEV and1
physiological measures of disease severity. In con- T L,CO and the WHOQOL-100 scores were found.
trast, Meenan et al. found for the AIMS pain scale Also health status was not related to duration of the
relationships with criteria of disease severity such as disease and routinely performed tests such as pul-
joint count [35]. However, the AIMS is a health monary function tests and serum angiotensin con-
status measure and the questions are closer related to verting enzyme (sACE) levels, respectively, as we
objective measures than the WHOQOL-100 items. showed in a previous study [7]. However, as men-
The questions of the latter assess, e.g. to what extent tioned above, fatigue was found related to higher
the patient has ‘difficulties to cope with pain or levels of CRP in sarcoidosis patients [37]. Although
discomfort’, ‘worries about pain or discomfort’, and the impairment of QOL was more severe in the RA
measure the ‘extent that pain keeps you from doing patients, QOL was considerably impaired in the
what you must do’. These questions assess rather the sarcoidosis patients as well. When only considering
patient’s subjective perception. The impairment the the pulmonary function tests, one would expect only
patient perceives by the pain is not necessarily mild impairment of QOL in these sarcoidosis pa-
related to measures such as functional status or tients, as these tests were normal in most patients, or
swollen joint count. showed only mild impairment.
RA patients with elevated CRP levels had low The present study has a couple of limitations.
levels of energy and more fatigue. This is in line Disease severity as assessed by the different, routine-
with other studies, in which improvement of fatigue ly performed physiological measures for both dis-
coincided with a descend of CRP levels after treat- orders are not directly comparable. Moreover, the
ment [36]. Previously, we found a relationship disease duration of the RA patients was longer than
between fatigue and CRP levels for sarcoidosis that of the sarcoidosis patients. Although one may
patients as well [37]. Moreover, we found that in hypothesize that duration of the disease influences
sarcoidosis patients, the symptom fatigue is assessed QOL, this was clearly not the case in both patient
more accurately by the WHOQOL-100 than by only groups. In addition, the RA patients were signifi-
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Self-evaluation processes and adjustment to rheumatoidcantly older than the sarcoidosis patients. This
arthritis. Arthritis Rheum 1988;31:1245–51.difference between the patient groups did not in-
[3] Long AF, Scott DL. Meeting Report. Measuring health statusfluence the results, as age was used as covariate in
and outcomes in rheumatoid arthritis within routine clinical
the analyses. practice. Br J Rheumatol 1994;33:682–5.
In conclusion, QOL is impaired in both RA as [4] Van Riel P, Van Lankveld W. Quality of life in rheumatoid
arthritis: a review. Pharm World Sci 1993;15:93–7.well as in sarcoidosis. As hypothesized, QOL was
[5] Meenan RF. The AIMS approach to health status measure-more seriously impaired and included more aspects
ment: conceptual background and measurement properties. Jof QOL in RA patients than in sarcoidosis patients.
Rheumatol 1982;9:785–8.
Main problems for both patient groups were sleeping [6] Bijlsma JWJ, Huiskes CJAE, Kraaimaat FW, Vanderveen MJ,
problems and fatigue. As expected, pain and im- Huber-Bruning O. Relation between patients’ own health
paired mobility were found only in the RA patients. assessment and clinical and laboratory findings in
rheumatoid arthritis. J Rheumatol 1991;18:650–3.However, in contrast to our expectations, with
[7] Drent M, Wirnsberger RM, Breteler MHM, Kock LMM, Derespect to their working capacity and problems
Vries J, Wouters EFM. Quality of life and depressiveperforming activities of daily living the two patient
symptoms in patients suffering from sarcoidosis. Sarcoidosis
groups did not show any differences. Although the Vasc Diffuse Lung Dis 1998;15:59–66.
disease impact on the quality of life was more severe [8] Wirnsberger RM, De Vries J, Breteler MHM, Van Heck GL,
Drent M. Evaluation of quality of life in sarcoidosis patients.in the RA patients, the impact of the disease on
Respir Med 1998;92:750–6.symptomatic sarcoidosis patients was considerable.
[9] Semenzato G, Zambello R, Trentin L, Agostini C. CellularThis study indicated that QOL indeed is partly
immunity in sarcoidosis and hypersensitivity pneumonitis.
related to physiological measures of disease severity Recent advances. Chest 1993;103(suppl):139S–43S.
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